Do you have probable Dementia with Lewy Bodies (DLB), Mild Cognitive Impairment with "high likelihood" DLB, or Parkinson's Disease Dementia (PDD)? You may be able to participate in an observational study to track your disease progression and promote future research.

The purpose of this study is to evaluate both sporadic (not inherited), and familial (inherited), forms of frontotemporal lobar degeneration (FTLD). Patients include both those who have symptoms of FTLD and those who do not (yet have a family history involving FTLD). This is an observational study, meaning that there is no investigational treatment involved. We will be working with patients for up to a 5 year period to learn more about FTLD using a neurological exam, tests of memory, behavior, and judgement, MRI, and biospecimen collection (blood and/or CSF). This study involves genetic testing of the genes so far identified to be associated with FTLD. The overall goal is to help better understand FTLD, to better understand the genetics of FTLD, and to use the information we learn to guide improved patient care and potential drug development.

The purpose of the study is to establish a Clinical Cohort (group) of research participants to examine normal cognition, mild cognitive impairment and Alzheimer's disease and related disorders (ADRD) as people get older. We will be measuring changes in your memory and the way you process information as you age. As part of the study, you will be asked to participate in yearly evaluations of your memory and health. You will have brain imagining done by Magnetic Resonance Imaging (MRI), a lumbar puncture and blood will be drawn at some visits. Also, as part of this research you must designate a "project partner." This should be someone who is familiar with your health and will be able to provide information about your health and wellbeing as appropriate.

The SHIMMER study is designed to evaluate the safety and effectiveness of the study drug CT1812 in adults with mild to moderate Dementia with Lewy Bodies (DLB). The purpose of this study is to learn how well you or your loved one tolerate(s) a once-a-day oral dose of CT1812. This research study will take place at multiple locations in the US. Qualified participants will be in this study for approximately 8 months.

The purpose of this study is to determine whether neflamapimod, in comparison to placebo, can improve learning skills, problem solving skills, and memory loss in people diagnosed with Dementia with Lewy Bodies.